No connection

Search Results

FMS vs JNJ

FMS
Fresenius Medical Care AG
BULLISH
Price
$22.77
Market Cap
$12.44B
Sector
Healthcare
AI Confidence
75%
JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
FMS
11.56
JNJ
21.55
Forward P/E
FMS
5.62
JNJ
18.9
P/B Ratio
FMS
0.81
JNJ
7.03
P/S Ratio
FMS
0.63
JNJ
6.09
EV/EBITDA
FMS
6.25
JNJ
17.81

Profitability

Gross Margin
FMS
25.62%
JNJ
68.08%
Operating Margin
FMS
11.68%
JNJ
23.97%
Profit Margin
FMS
4.98%
JNJ
28.46%
ROE
FMS
7.93%
JNJ
35.03%
ROA
FMS
3.62%
JNJ
8.68%

Growth

Revenue Growth
FMS
-0.3%
JNJ
9.1%
Earnings Growth
FMS
420.0%
JNJ
48.6%

Financial Health

Debt/Equity
FMS
0.76
JNJ
0.6
Current Ratio
FMS
1.26
JNJ
1.03
Quick Ratio
FMS
0.85
JNJ
0.69

Dividends

Dividend Yield
FMS
3.58%
JNJ
2.19%
Payout Ratio
FMS
42.76%
JNJ
46.6%

AI Verdict

FMS BULLISH

FMS presents a classic deep-value opportunity, characterized by a stable Piotroski F-Score of 6/9 and a current price ($22.77) trading significantly below both its Graham Number ($35.27) and Intrinsic Value ($58.12). While top-line revenue growth is stagnant (-0.30%), the company has demonstrated a massive recovery in earnings and maintains a sustainable dividend payout ratio of 42.76%. The valuation is exceptionally attractive with a Forward P/E of 5.62 and a Price/Book of 0.81. However, the bullish value thesis is countered by a completely bearish technical trend and weak insider sentiment, suggesting a 'value trap' risk if revenue does not stabilize.

Strengths
Significant undervaluation relative to Graham Number and Intrinsic Value
Strong earnings recovery with YoY growth of 420%
Attractive valuation multiples (P/B 0.81, P/S 0.63, Forward P/E 5.62)
Risks
Stagnant revenue growth (-0.30% YoY) indicating a lack of top-line momentum
Severe bearish technical trend (0/100 score)
Low insider sentiment (40/100) suggesting lack of internal confidence
JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69

Compare Another Pair

FMS vs JNJ: Head-to-Head Comparison

This page compares Fresenius Medical Care AG (FMS) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile